Overview
MGNX market data
Price History
MGNX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.18 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -44.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.29 – $5.08 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $255.5M · P/B 1.83 · P/S 1.63.
Company News
UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M EstimateBenzinga · Aug 13, 2026, 9:52 PM
Macrogenics Q2 EPS $(0.31) Misses $0.02 Estimate, Sales $32.832M Miss $67.456M EstimateBenzinga · Aug 13, 2026, 8:32 PM
8-K filing — MACROGENICS INC (MGNX)SEC EDGAR · Aug 13, 2026, 8:07 PM
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M PaymentBenzinga · Aug 11, 2026, 8:22 PM
MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27Benzinga · Jul 23, 2026, 8:06 PM
MacroGenics To Receive $24.5M Milestone From Sanofi Following FDA Approval Of TZIELD Expansion In Type 1 DiabetesBenzinga · Jun 22, 2026, 8:45 PM